Literature DB >> 15094112

A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motifs: the ADAMTS family.

Suneel S Apte1.   

Abstract

ADAMTS proteases are complex secreted enzymes containing a prometalloprotease domain of the reprolysin type attached to an ancillary domain with a highly conserved structure that includes at least one thrombospondin type 1 repeat. Known functions of ADAMTS proteases include processing of procollagens and von Willebrand factor as well as catabolism of aggrecan, versican and brevican. They have been demonstrated to have important roles in connective tissue organization, coagulation, inflammation, arthritis, angiogenesis and cell migration. ADAMTS can be grouped into distinct clades within which there is conservation of modular organization, protein sequence, gene structure and possibly, of substrate preference. ADAMTS proteases are synthesized as zymogens, with constitutive proprotein convertase removal of the propeptide occurring prior to secretion. Their enzymatic specificity is heavily influenced by their ancillary domain, which plays a critical role in directing these enzymes to their substrates, the cell surface and the extracellular matrix.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15094112     DOI: 10.1016/j.biocel.2004.01.014

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  85 in total

1.  Genetic variations in the ADAMTS12 gene are associated with schizophrenia in Puerto Rican patients of Spanish descent.

Authors:  Irina N Bespalova; Gary W Angelo; Ben P Ritter; Jason Hunter; Maria L Reyes-Rabanillo; Larry J Siever; Jeremy M Silverman
Journal:  Neuromolecular Med       Date:  2012-02-10       Impact factor: 3.843

Review 2.  Lectican proteoglycans, their cleaving metalloproteinases, and plasticity in the central nervous system extracellular microenvironment.

Authors:  M D Howell; P E Gottschall
Journal:  Neuroscience       Date:  2012-05-22       Impact factor: 3.590

3.  Granulin-epithelin precursor binds directly to ADAMTS-7 and ADAMTS-12 and inhibits their degradation of cartilage oligomeric matrix protein.

Authors:  Fengjin Guo; Yongjie Lai; Qingyun Tian; Edward A Lin; Li Kong; Chuanju Liu
Journal:  Arthritis Rheum       Date:  2010-07

4.  Tumor growth inhibitory effect of ADAMTS1 is accompanied by the inhibition of tumor angiogenesis.

Authors:  Masanari Obika; Hiroko Ogawa; Katsuyuki Takahashi; Jiayi Li; Omer Faruk Hatipoglu; Mehmet Zeynel Cilek; Toru Miyoshi; Junko Inagaki; Takashi Ohtsuki; Shozo Kusachi; Yoshifumi Ninomiya; Satoshi Hirohata
Journal:  Cancer Sci       Date:  2012-08-29       Impact factor: 6.716

Review 5.  Current concepts in thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

6.  ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2.

Authors:  Nathan V Lee; Makoto Sato; Douglas S Annis; Joseph A Loo; Lily Wu; Deane F Mosher; M Luisa Iruela-Arispe
Journal:  EMBO J       Date:  2006-11-02       Impact factor: 11.598

7.  Tissue-specific induction of ADAMTS2 in monocytes and macrophages by glucocorticoids.

Authors:  Thomas P J Hofer; Marion Frankenberger; Jörg Mages; Roland Lang; Peter Meyer; Reinhard Hoffmann; Alain Colige; Löms Ziegler-Heitbrock
Journal:  J Mol Med (Berl)       Date:  2007-12-14       Impact factor: 4.599

8.  A case of Weill-Marchesani syndrome with inversion of chromosome 15.

Authors:  Jae Lim Chung; Sun Woong Kim; Ji Hyun Kim; Tae-Im Kim; Hyung Keun Lee; Eung Kweon Kim
Journal:  Korean J Ophthalmol       Date:  2007-12

Review 9.  Regulation of thrombospondin1 by extracellular proteases.

Authors:  M Luisa Iruela-Arispe
Journal:  Curr Drug Targets       Date:  2008-10       Impact factor: 3.465

10.  The secreted AdamTS-A metalloprotease is required for collective cell migration.

Authors:  Afshan Ismat; Alan M Cheshire; Deborah J Andrew
Journal:  Development       Date:  2013-03-27       Impact factor: 6.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.